Page 3«..2345..10..»

Archive for the ‘Neuropathy’ Category

Waldenstrm Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up – Hematology Advisor

Tuesday, September 15th, 2020

The combination of the ixazomib, dexamethasone, and rituximab (IDR) yields durable responses and maintains an excellent safety profile in patients with Waldenstrm macroglobulinemia (WM), according to results of a study published in Blood Advances.

The investigators elected to assess IDR due to the favorable safety profile of ixazomib, in particular a low incidence of neuropathy, in multiple myeloma.

The long-term follow-up results included all 26 treatment-naive patients with WM who participated in the prospective, phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02400437) that evaluated the combination of IDR.

For the study, IDR was administered over 12 cycles: six 4-week induction cycles followed by six 8-week maintenance cycles.

All patients had the MYD88 L265P mutation, and CXCR4 mutations were present in 15 patients (58%). The median age at treatment initiation was 65 years (range, 46-82 years).

The median time to response was 2 months, and the median time to major response was 6 months. CXCR4 mutation status appeared to have an effect on the time to response; patients with CXCR4 mutations had a longer median time to response than those without mutations (3 months vs 1 month, respectively; P =.003). However, no significant difference was observed in the median time to major response between the genotypes (10 months vs 3 months, respectively; P =.31).

IDR induced high rates of response among the cohort. The overall response rate was 96% (95% CI, 80-100) while the major response rate was 77% (95% CI, 56-91). At best response, 19% of patients achieved a very good partial response (VGPR), 58% achieved a partial response, 19% had a minor response, and 4% had stable disease. The rate of VGPR was higher in patients without CXCR4 mutations than in patients with CXCR4 mutations (36% vs 7%; P =.06).

Among all patients, the median progression-free survival and median duration of response (DOR) was 40 months and 38 months, respectively. The median time to next treatment was also 40 months. None of these outcomes were associated with CXCR4 mutational status.

The safety profile was considered excellent, although some patients experienced grade 3 adverse events, which included infections (2 patients, unrelated to treatment), hyperglycemia (2 patients, from dexamethasone), infusion reactions (2 patients, with rituximab), and neuropathy (1 patients, due to uncontrolled diabetes). No grade 4 adverse events or deaths occurred.

The authors concluded, On the basis of the findings of our study, IDR represents an easy-to-administer, safe, and effective treatment option for patients with WM, with high rates of durable responses and an excellent adverse event profile.

Disclosures: Some authors have declared affiliations with or received funding from the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrm macroglobulinemia: long-term follow-up. Blood Adv. 2020;4(16):3952-3959. doi:10.1182/bloodadvances.2020001963

Continue reading here:
Waldenstrm Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up - Hematology Advisor

Read More...

Chemotherapy Induced Peripheral Neuropathy Market Set To Register A CAGR Growth Of XX% Over The Forecast Period 2019 2029 – Daily Research Chronicle

Tuesday, September 15th, 2020

In this report, the global Chemotherapy Induced Peripheral Neuropathy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Chemotherapy Induced Peripheral Neuropathy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Chemotherapy Induced Peripheral Neuropathy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Chemotherapy Induced Peripheral Neuropathy market to assist our clients arrive at beneficial business decisions.

The Chemotherapy Induced Peripheral Neuropathy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Chemotherapy Induced Peripheral Neuropathy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/30209

Resourceful insights enclosed in the report:

The major players profiled in this Chemotherapy Induced Peripheral Neuropathy market report include:

key players and product offerings

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/30209

The market report addresses the following queries related to the Chemotherapy Induced Peripheral Neuropathy market:

The study objectives of Chemotherapy Induced Peripheral Neuropathy Market Report are:

To analyze and research the Chemotherapy Induced Peripheral Neuropathy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Chemotherapy Induced Peripheral Neuropathy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Chemotherapy Induced Peripheral Neuropathy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Chemotherapy Induced Peripheral Neuropathy market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/30209

Read more:
Chemotherapy Induced Peripheral Neuropathy Market Set To Register A CAGR Growth Of XX% Over The Forecast Period 2019 2029 - Daily Research Chronicle

Read More...

Neuropathy Pain Treatment Market Analysis Highlights the Impact of COVID-19 (2020-2024) |Presence of Large Patient Pool to boost the Market Growth |…

Thursday, September 3rd, 2020

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1.70 billion during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. The presence of large patient pool will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Neuropathy Pain Treatment Market 2020-2024: Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The neuropathy pain treatment market report covers the following areas:

This study identifies growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by drug class

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Visit link:
Neuropathy Pain Treatment Market Analysis Highlights the Impact of COVID-19 (2020-2024) |Presence of Large Patient Pool to boost the Market Growth |...

Read More...

No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter…

Thursday, September 3rd, 2020

The pathophysiology of pain in neuropathy is complex and may be linked to sensory phenotypes. Quantitative sensory testing, a standardized method to evaluate sensory profiles in response to defined stimuli, assesses functional integrity of small and large nerve fiber afferents and central somatosensory pathways. It has revealed detailed insights into mechanisms of neuropathy, yet, it remains unclear if pain directly affects sensory profiles. The main objective of this study was to investigate sensory profiles in patients with various neuropathic conditions, including polyneuropathy, mononeuropathy, and lesions to the central nervous system, in relation to self-reported presence or absence of pain and pain sensitivity using the Pain Sensitivity Questionnaire.A total of 443 patients (332 painful and 111 painless) and 112 healthy participants were investigated. Overall, loss of sensation was equally prevalent in patients with and without spontaneous pain. Pain thresholds were equally lowered in both patient groups, demonstrating that hyperalgesia and allodynia is just as present in patients not reporting any pain. Remarkably, this was similar for dynamic mechanical allodynia. Hypoalgesia was more pronounced in painful polyneuropathy whereas hyperalgesia was more frequent in painful mononeuropathy (compared to painless conditions). Self-reported pain sensitivity was significantly higher in painful than in painless neuropathic conditions.Our results reveal the presence of hyperalgesia and allodynia in patients with central and peripheral lesions of the somatosensory system not reporting spontaneous pain. This shows that symptoms and signs of hypersensitivity may not necessarily coincide, and that painful and painless neuropathic conditions may mechanistically blend into one another.

PubMed

View post:
No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter...

Read More...

Neuropathy May Be Primary Cause of Upper Limb Dysfunction in Breast Cancer Survivors, Study Finds – Oncology Nurse Advisor

Thursday, September 3rd, 2020

More than half of women who underwent treatment for breast cancer experienced physical/functional complications involving an upper limb, according to results of a cross-sectional study published in Supportive Care in Cancer.1

Although a high incidence of posttreatment upper limb dysfunction has been previously reported in survivors of breast cancer, the aim of this study was to take a closer look at the underlying causes of this condition in women with a history of breast cancer.

Knowing what actually influences the development of upper limb dysfunction after breast cancer treatment can help healthcare professionals minimize the incidence of this complication, thus reducing the physical and functional impact of the disease and providing a better quality of life of survivors, the study authors commented.

This study involved adult women who had received breast cancer treatment between 2009 and 2016 at 1 of 2 institutions in Brazil.

Data related to sociodemographic characteristics and treatment history were collected during a patient interview and/or review of the patient medical record. The Disabilities of Arm, Shoulder and Hand (DASH) questionnaire was used to assess the impact of breast cancer treatment on the upper limb.2

Regarding the selection of the DASH questionnaire, the study authors explained that most of the instruments used to assess complications include physical examination with measurement of range of motion, muscle strength, and sensory capacity, and because they are limited to physical issues, many are unable to identify the level of independence and functionality for performing daily life activities related to the upper limbs.

They further clarified that the incorporation of patient-reported outcome measures into the DASH questionnaire also allowed for assessment of patient quality of life.

Other patient assessments included evaluations for the presence of lymphedema in the upper limb, breast skin sensitivity, paresthesia, pain, and scar adherence.

Of the 233 women included in this study, the mean patient age was 56.3 years. All patients underwent surgery for breast cancer with an average of approximately 5 years between surgical treatment and assessment. Lymphadenectomy was performed in 60.2% of patients, with the remaining patients having undergone either sentinel lymph node dissection or no surgical assessment of the lymph nodes. Approximately three-quarters of patients had received chemotherapy, radiation therapy, and were overweight/obese based on body mass index (BMI).

Key study findings included some level of upper limb dysfunction and evidence for sensory intercostobrachial nerve damage in 55.4% and 47.2% of patients, respectively.

Of note, analyses based on models adjusted for age and BMI showed that only paresthesia due to intercostobrachial nerve damage was significantly associated with upper limb dysfunction in these patients (odds ratio [OR], 1.96; 95% CI, 1.06-3.60; P =.03).

In summarizing the findings from this study, the study authors stated that upper limb dysfunction is a frequent complication after breast cancer treatment and may be associated with neuropathies due to changes in the intercostobrachial nerve pathway.

Reference

1. Siqueria TC, Fragoas SP, Pelegrini A, de Oliveira AR, Medeiros da Luz C. Factors associated with upper limb dysfunction in breast cancer survivors. Support Care Cancer. Published online August 17, 2020. doi:10.1007/s00520-020-05668-7

2. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther. 2001;14(2):128-146.

Visit link:
Neuropathy May Be Primary Cause of Upper Limb Dysfunction in Breast Cancer Survivors, Study Finds - Oncology Nurse Advisor

Read More...

Demand for Diabetic Neuropathy Market to Witness Rapid Surge During the Period 2015 2021 – thedailychronicle.in

Thursday, September 3rd, 2020

Diabetic neuropathy refers to the nerve damage caused due to diabetes. Diabetic neuropathy most often damages nerves in the legs and feet. However, it can injure nerve fibers throughout the body. Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes. Increasing diabetic population and growing awareness among people about diabetes and related complications are some of the major factors that drive the diabetic neuropathy market. Types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and other diabetic nerve damage. The peripheral diabetic neuropathy affects the feet and legs. It causes loss of sensation, and sometimes pain in the feet, legs, and hands. Autonomic diabetic neuropathy affects body functions such as heart rate, blood pressure, perspiration, and digestion. Proximal diabetic neuropathy affects thighs, hips, buttocks, and legs. Focal diabetic neuropathy affects the nerves, most often in the wrist, thigh, or foot. In addition, it also affects the nerves of the back, chest, and the nerves that control the eye muscles. Some of the factors that cause nerve damage in diabetes condition includes poor blood sugar control, kidney disease, smoking, excess weight, and length of time to have diabetes. However, anyone who has diabetes can develop neuropathy. Some symptoms of diabetic neuropathy are pain, tingling, numbness, and loss of feeling in the hands, arms, feet, and legs. The treatment options for diabetic neuropathy include drugs, radiotherapy, and physiotherapy.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/4795

The global diabetic neuropathy market is categorized based on medication, radiotherapy, and physiotherapy. Based on medication, the report covers antispasmodic, antidepressant, and others. Based on radiotherapy, the market comprises transcutaneous electrical nerve stimulation (TENS).

North America has the largest market for diabetic neuropathy, followed by Europe. This is due to the increasing number of patients with diabetes, rise in research and development activities, increasing awareness among people about diabetes and related complications, and improved healthcare infrastructure in the region. The diabetic neuropathy market in Asia is expected to experience high growth rate in the next few years. This is due to rising R&D activities for drug discovery and development, increasing government supports in the form of funding, growing awareness about diabetic neuropathy, and developing healthcare infrastructure in the region. In addition, growing demographics and economies in the developing countries such as India, China, and Japan are expected to lead growth in the diabetic neuropathy market in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/4795

Increasing prevalence of diabetes cases, growing, aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes and related nerve complications, and rise in R&D activities in drug discovery and developmemt are the key factors driving the global diabetic neuropathy market. However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs are some of the factors restraining the growth for global diabetic neuropathy market.

Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed in the global diabetic neuropathy market.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/4795

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
Demand for Diabetic Neuropathy Market to Witness Rapid Surge During the Period 2015 2021 - thedailychronicle.in

Read More...

Neuropathy Pain Treatment Market 10-Year Market Forecast and Trends Analysis Research Report – Scientect

Thursday, September 3rd, 2020

In 2029, the Neuropathy Pain Treatment market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Neuropathy Pain Treatment market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Neuropathy Pain Treatment market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Neuropathy Pain Treatment market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2641417&source=atm

Global Neuropathy Pain Treatment market report on the basis of market players

The report examines each Neuropathy Pain Treatment market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Neuropathy Pain Treatment market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Neuropathy Pain Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuropathy Pain Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuropathy Pain Treatment market.The following players are covered in this report:PfizerDepomedEli LillyEndoGrnenthal GroupArbor PharmaceuticalsNeuropathy Pain Treatment Breakdown Data by TypeCalcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthersNeuropathy Pain Treatment Breakdown Data by ApplicationRetail PharmaciesHospitalsOthers

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2641417&source=atm

The Neuropathy Pain Treatment market report answers the following queries:

The Neuropathy Pain Treatment market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2641417&licType=S&source=atm

Research Methodology of Neuropathy Pain Treatment Market Report

The global Neuropathy Pain Treatment market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Neuropathy Pain Treatment market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Neuropathy Pain Treatment market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read the original here:
Neuropathy Pain Treatment Market 10-Year Market Forecast and Trends Analysis Research Report - Scientect

Read More...

Peripheral Neuropathy Treatment Market Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand and Forecast till 2025 – Express Journal

Thursday, September 3rd, 2020

The research report on Peripheral Neuropathy Treatment market Size provides a thorough assessment of this business vertical. As per the study, the market is predicted to accumulate significant revenues and showcase a substantial growth rate during the estimated timeframe.

The Peripheral Neuropathy Treatment market report is a thorough investigation of the industry in terms of consumption and production. The report, based on the production facet, encompasses details regarding the manufacturing structure and profit margins of the renowned manufacturers. The price incurred by the companies to produce, store, and sell one unit of a product across the various geographies over the analysis period are also included in the study.

Speaking of the consumption aspect, the study details the consumption value and consumption volume of the products in question. Data pertaining to the individual sales price along with the import and export patterns spanning various territories are delivered in the report. Additionally, the report also predicts the production and consumption patterns over the assessment period.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/185890

Key pointers from the competitive landscape:

An outline of the regional landscape:

A brief overview of the product spectrum:

A summary of the application terrain:

In conclusion, the report evaluates the Peripheral Neuropathy Treatment market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are duly presented in the report.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/185890

Continued here:
Peripheral Neuropathy Treatment Market Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand and Forecast till 2025 - Express Journal

Read More...

Post-pandemic Analysis on Neuropathy Pain Treatment Market Likely to Emerge Over A Period Of 2020 2029 – Galus Australis

Thursday, September 3rd, 2020

The latest report on 2020-2029 Report on Global Neuropathy Pain Treatment Market by Player, Region, Type, Application and Sales Channel gives a broad assessment of the global Neuropathy Pain Treatment market by categorizing it in terms applications, types, and regions. The report gives a detailed analysis on competitive landscape and strategies that influenced the market in a positive way. Further, the report gives an overview of current market dynamics by studying various key segments based on the product, types, applications, end-to-end industries and market scenario.

Major Key Playersof Neuropathy Pain Treatment Market Report:Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Request a sample of this report @ https://www.regalintelligence.com/request-sample/159875

Market split by Type, can be divided into:

Calcium Channel Alpha 2-Delta Ligands

Serotonin-Norepinephrine Reuptake Inhibitors

Others

Market split by Application, can be divided into:

Retail Pharmacies

Hospitals

Others

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Market segment by Region/Country including:

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

Reach us to quote the effective price of this report @https://www.regalintelligence.com/check-discount/159875

Table of Contents

Chapter 1 Neuropathy Pain Treatment Market Overview

1.1 Neuropathy Pain Treatment Definition

1.2 Global Neuropathy Pain Treatment Market Size Status and Outlook (2014-2029)

1.3 Global Neuropathy Pain Treatment Market Size Comparison by Region (2014-2029)

1.4 Global Neuropathy Pain Treatment Market Size Comparison by Type (2014-2029)

1.5 Global Neuropathy Pain Treatment Market Size Comparison by Application (2014-2029)

1.6 Global Neuropathy Pain Treatment Market Size Comparison by Sales Channel (2014-2029)

1.7 Neuropathy Pain Treatment Market Dynamics (COVID-19 Impacts)

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Mergers/Acquisitions/Expansion)

1.7.4 COVID-19 Impacts on Current Market

1.7.5 Post-Strategies of COVID-19 Outbreak

Chapter 2 Neuropathy Pain Treatment Market Segment Analysis by Player

2.1 Global Neuropathy Pain Treatment Sales and Market Share by Player (2017-2019)

2.2 Global Neuropathy Pain Treatment Revenue and Market Share by Player (2017-2019)

2.3 Global Neuropathy Pain Treatment Average Price by Player (2017-2019)

2.4 Players Competition Situation & Trends

2.5 Conclusion of Segment by Player

Chapter 3 Neuropathy Pain Treatment Market Segment Analysis by Type

3.1 Global Neuropathy Pain Treatment Market by Type

3.1.1 Calcium Channel Alpha 2-Delta Ligands

3.1.2 Serotonin-Norepinephrine Reuptake Inhibitors

3.1.3 Others

3.2 Global Neuropathy Pain Treatment Sales and Market Share by Type (2014-2019)

3.3 Global Neuropathy Pain Treatment Revenue and Market Share by Type (2014-2019)

3.4 Global Neuropathy Pain Treatment Average Price by Type (2014-2019)

3.5 Leading Players of Neuropathy Pain Treatment by Type in 2019

3.6 Conclusion of Segment by Type

Chapter 4 Neuropathy Pain Treatment Market Segment Analysis by Application

4.1 Global Neuropathy Pain Treatment Market by Application

4.1.1 Retail Pharmacies

4.1.2 Hospitals

4.1.3 Others

4.2 Global Neuropathy Pain Treatment Sales and Market Share by Application (2014-2019)

4.3 Leading Consumers of Neuropathy Pain Treatment by Application in 2019

4.4 Conclusion of Segment by Application

Chapter 5 Neuropathy Pain Treatment Market Segment Analysis by Sales Channel

5.1 Global Neuropathy Pain Treatment Market by Sales Channel

5.1.1 Direct Channel

5.1.2 Distribution Channel

5.2 Global Neuropathy Pain Treatment Sales and Market Share by Sales Channel (2014-2019)

5.3 Leading Distributors/Dealers of Neuropathy Pain Treatment by Sales Channel in 2019

5.4 Conclusion of Segment by Sales Channel

Chapter 6 Neuropathy Pain Treatment Market Segment Analysis by Region

6.1 Global Neuropathy Pain Treatment Market Size and CAGR by Region (2014-2029)

6.2 Global Neuropathy Pain Treatment Sales and Market Share by Region (2014-2019)

6.3 Global Neuropathy Pain Treatment Revenue and Market Share by Region (2014-2019)

6.4 North America

6.4.1 North America Market by Country

6.4.2 North America Neuropathy Pain Treatment Market Share by Type

6.4.3 North America Neuropathy Pain Treatment Market Share by Application

6.4.4 United States

6.4.5 Canada

6.4.6 Mexico

6.5 Europe

6.5.1 Europe Market by Country

6.5.2 Europe Neuropathy Pain Treatment Market Share by Type

6.5.3 Europe Neuropathy Pain Treatment Market Share by Application

6.5.4 Germany

6.5.5 UK

6.5.6 France

6.5.7 Italy

6.5.8 Russia

6.5.9 Spain

6.6 Asia-Pacific

6.6.1 Asia-Pacific Market by Country

6.6.2 Asia-Pacific Neuropathy Pain Treatment Market Share by Type

6.6.3 Asia-Pacific Neuropathy Pain Treatment Market Share by Application

6.6.4 China

6.6.5 Japan

6.6.6 Korea

6.6.7 India

6.6.8 Southeast Asia

6.6.9 Australia

6.7 South America

6.7.1 South America Market by Country

6.7.2 South America Neuropathy Pain Treatment Market Share by Type

Excerpt from:
Post-pandemic Analysis on Neuropathy Pain Treatment Market Likely to Emerge Over A Period Of 2020 2029 - Galus Australis

Read More...

Could Bee Venom Be the Key to Treating Triple-Negative Breast Cancer? – PharmaLive

Thursday, September 3rd, 2020

A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.

Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia led the research. She and her colleagues tested the effect of venom on clinical subtypes of breast cancer, using the venom from 312 honeybees and bumblebees from Perth Western Australia, Ireland and England.

No one had previously compared the effects of honeybee venom or melittin across all of the different subtypes of breast cancer and normal cells, Dr. Duffy said. We tested honeybee venom on normal breast cells, and cells from the clinical subtypes of breast cancer: hormone receptor positive, HER2-enriched, and triple-negative breast cancer.

Dr. Duffy explained that the goal of the research was ultimately to determine if honeybee venom and its component compound, melittin, had anti-cancer properties.

We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells, said Dr. Duffy. The venom was extremely potent.

Melittin, in particular, also had a surprising effect. Within 20 minutes, the compound was able to reduce the chemical messages of cancer cells that are necessary for growth and cell division.

We looked at how honeybee venom and melittin affect the cancer signaling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signaling pathways were shut down, said Dr. Duffy. Melittin modulated the signaling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer.

Western Australias Chief Scientist Professor Peter Klinken noted that this study significantly demonstrates the potential benefits of melittin, and overall, how compounds in nature can be utilized to combat human diseases.

The researchers note that studies will be necessary to formally assess the best way to deliver melittin to patients.

This is not the only positive news that has come out of the breast cancer treatment realm as of late. Athenex also announced on Sept. 1 that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application for oral paclitaxel and encequidar for the treatment of metastatic breast cancer, and it has been granted Priority Review.

We see oral paclitaxel as a potentially important alternative to IV infusions, especially during the current pandemic, as it may allow cancer patients to take the oral chemotherapy at home, said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex. We believe the oral paclitaxel program validates our broader Orascovery platform, and we are committed to applying the technology to convert other IV chemotherapies into oral agents.

The NDA is based on data from a Phase 3 study of oral paclitaxel for the treatment of metastatic breast cancer. The trial was randomized and controlled, and looked at the safety and efficacy of oral paclitaxel monotherapy against IV paclitaxel monotherapy. It achieved its primary endpoint, demonstrating a statistically significant improvement in overall response rate, along with a lower neuropathy, compared to IV paclitaxel.

The FDA grants Priority Review to NDAs for potential drugs that, if approved, would make significant improvements to the way patients are treated for serious conditions, such as various types of cancer.

See the article here:
Could Bee Venom Be the Key to Treating Triple-Negative Breast Cancer? - PharmaLive

Read More...

Even after the infection is gone, symptoms linger for COVID-19 ‘long-haulers’ – Omaha World-Herald

Thursday, September 3rd, 2020

Erin Bryant, a physical therapist with Fyzical Therapy, said the body and the brain have the ability to heal with time. In Thieles case, she said, muscle memory and her former level of fitness will aid her recovery.

The therapy practice currently is working with three patients who have had COVID-19, including Thiele. All three cases are different, and all will require different treatment.

Theres no cookie-cutter for this, she said.

Christine Thiele, of Omaha, does a physical therapy session focusing on balance at WW Gym Wellness Workout in Omaha on Wednesday, August 26, 2020. Thiele had COVID-19 in the spring and is still struggling with lingering effects having to do with memory, balance and neuropathy.

Meanwhile, support groups for patients who have had COVID-19 have formed on Facebook and other forums. A group called Body Politic, which includes COVID-19 survivors, also has been involved in research.

Thiele has written about her situation on Facebook. She said doctors believe the virus triggered an autoimmune disease that has affected her mobility.

In the beginning, I was really trying to educate people to take this seriously, she said. Now its like, Look what its done to me. You guys really have to take it seriously.

Steve Schrader, too, has had a long road back.

Now 65, the La Vista man started in mid-March to experience symptoms, which he attributed to allergies. Those symptoms morphed into chest congestion and what he thought was a sinus infection. Schrader, who has asthma, battled it for a couple of weeks, as he usually does with chest congestion, including using a nebulizer.

See original here:
Even after the infection is gone, symptoms linger for COVID-19 'long-haulers' - Omaha World-Herald

Read More...

American Neurological Association Hosts First-Ever All-Virtual Annual Meeting – PR Newswire India

Thursday, September 3rd, 2020

MOUNT LAUREL, New Jersey, Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

https://2020.myana.org

SOURCE American Neurological Association

Continue reading here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PR Newswire India

Read More...

Global Impact of Covid-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market to Record Significant Revenue Growth During the Forecast…

Saturday, August 22nd, 2020

The Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry study now available at Grand View Report, is a detailed sketch of the business sphere in terms of current and future trends driving the profit matrix. The report also indicates a pointwise outline of market share, market size, industry partakers, and regional landscape along with statistics, diagrams, & charts elucidating various noteworthy parameters of the industry landscape.

The Chemotherapy Induced Peripheral Neuropathy Treatment Market research report offers an exhaustive analysis of this business space. The key trends that define the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market during the analysis timeframe are mentioned in the report, alongside other factors such as regional scope and regulatory outlook. Also, the document elaborates on the impact of current industry trends on key market driving factors as well as top challenges.

Request a sample Report of Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry Market at:https://grandviewreport.com/sample/8560

Covid-19 pandemic affects most industries in the globe. Here at Grand View Report we offer you comprehensive data of related industry which will help and support your business in all possible ways.

Top Key Players Profiled in This Report: , Achelios Therapeutics Inc, Advinus Therapeutics Ltd, Apollo Endosurgery Inc, Aptinyx Inc, Asahi Kasei Pharma Corp, Can-Fite BioPharma Ltd, Celgene Corp, DermaXon LLC, Eisai, Immune Pharmaceuticals Inc, INSYS Therapeutics Inc, Kineta Inc, KPI Therapeutics Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc, Mundipharma International Ltd, Nemus Bioscience Inc, Neurocentrx Pharma Ltd, Panacea Pharmaceuticals Inc, PeriphaGen Inc, PharmatrophiX Inc, PledPharma AB, Sova Pharmaceuticals Inc, Virobay Inc, WEX Pharmaceuticals Inc

The study also provides with a summary of the competitive spectrum as well as an in-depth assessment of the raw materials and downstream buyers.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

Our study helps to acquire the following:

Elaborating on the competitive landscape of Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market:

A gist of the regional scope of the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market:

Ask for Discount on Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry Market Report at:https://grandviewreport.com/discount/8560

Other information mentioned in the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market report:

The report answers important questions that companies may have when operating in the global Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market. Some of the questions are given below:

For More Details On this Report:http://grandviewreport.com/industry-growth/Chemotherapy-Induced-Peripheral-Neuropathy-Treatment-Market-8560

See the rest here:
Global Impact of Covid-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market to Record Significant Revenue Growth During the Forecast...

Read More...

Diabetic Neuropathy Market :How The Will Perform In Upcoming Years Based On Size, Share And Demand In Major Regions | 2020-2026 – The News Brok

Saturday, August 22nd, 2020

Global Diabetic Neuropathy Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the Global Diabetic Neuropathy Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Diabetic Neuropathy Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Diabetic Neuropathy market between 2020 and 2027. In terms of value, the Diabetic Neuropathy industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Get Free Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

The key players profiled in this report include: Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion ofDiabetic Neuropathy

o The micro-level analysis is conducted based on its product types, end-user applications, and geographic

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Diabetic Neuropathy market

Table of Contents

Report Overview: It includes the Diabetic Neuropathy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Diabetic Neuropathy market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Diabetic Neuropathy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in theDiabetic Neuropathy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/213

The research study can answer the following Key questions:

What will be the progress rate of the Diabetic Neuropathy Market for the conjecture period, 2020-2027?What are the prominent factors driving the Diabetic Neuropathy Market across different regions?Who are the major vendors dominating the Diabetic Neuropathy industry and what are their winning strategies?What will be the market scope for the estimated period?What are the major trends shaping the expansion of the industry in the coming years?What are the challenges faced by the Diabetic Neuropathy Market?

Major Highlights of TOC:

Chapter One: GlobalDiabetic Neuropathy Market Industry Overview

1.1Diabetic Neuropathy Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2Diabetic Neuropathy Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: GlobalDiabetic Neuropathy Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Diabetic Neuropathy Market Size by Demand

2.3 Global Diabetic Neuropathy Market Forecast by Demand

Chapter Three: GlobalDiabetic Neuropathy Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2Diabetic Neuropathy Market Size by Type

3.3Diabetic Neuropathy Market Forecast by Type

Chapter Four: Major Region ofDiabetic Neuropathy Market

4.1 Global Diabetic Neuropathy Sales

4.2 Global Diabetic Neuropathy Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Continued here:
Diabetic Neuropathy Market :How The Will Perform In Upcoming Years Based On Size, Share And Demand In Major Regions | 2020-2026 - The News Brok

Read More...

Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 – Owned

Saturday, August 22nd, 2020

The Cardiac Autonomic Neuropathy Treatment Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Cardiac Autonomic Neuropathy Treatment market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Cardiac Autonomic Neuropathy Treatment market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

The worldwide Cardiac Autonomic Neuropathy Treatment market is an enlarging field for top market players,

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

This Cardiac Autonomic Neuropathy Treatment report begins with a basic overview of the market. The analysis highlights the opportunity and Cardiac Autonomic Neuropathy Treatment industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Cardiac Autonomic Neuropathy Treatment insight regarding the things which are driving and affecting the earnings of the market. The Cardiac Autonomic Neuropathy Treatment report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

Research objectives and Reason to procure this report:-

Finally, the global Cardiac Autonomic Neuropathy Treatment market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Cardiac Autonomic Neuropathy Treatment industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Excerpt from:
Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 - Owned

Read More...

Value of Diabetic Neuropathy Market Predicted to Surpass US$ by the of 2015 2021 – Scientect

Sunday, August 16th, 2020

The Diabetic Neuropathy Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Diabetic Neuropathy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Diabetic Neuropathy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/4795

The worldwide Diabetic Neuropathy market is an enlarging field for top market players,

the top players

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/4795

This Diabetic Neuropathy report begins with a basic overview of the market. The analysis highlights the opportunity and Diabetic Neuropathy industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Diabetic Neuropathy insight regarding the things which are driving and affecting the earnings of the market. The Diabetic Neuropathy report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/4795

Research objectives and Reason to procure this report:-

Finally, the global Diabetic Neuropathy market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Diabetic Neuropathy industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Read the original here:
Value of Diabetic Neuropathy Market Predicted to Surpass US$ by the of 2015 2021 - Scientect

Read More...

Is there any help for chemotherapy-induced neuropathy? – STLtoday.com

Sunday, August 16th, 2020

I have often tried gabapentin (Neurontin) or a similar drug, pregabalin (Lyrica), but have not had much success. Duloxetine (Cymbalta) has evidence showing effectiveness at reducing pain and improving numbness, and those treated with duloxetine had a better quality of life than those on placebo. Finally, a preliminary trial showed a compounded cream containing baclofen, amitriptyline and ketamine showed some benefit.

Dear Dr. Roach An ear, nose and throat specialist told me not to use nasal sprays that contain oxymetazoline, such as Afrin, since over time they will damage and erode the tissues of the septum and inner nose. He said to use simple salt solution instead. Is this true? I used two shots of this nasal spray, and it cleared my sinuses and nose but was very uncomfortable. I have to be careful since I have had a constructive rhinoplasty and a septoplasty with reduced tissues. S.L.

Answer I agree wholeheartedly with your ENT doctor that long-term use of oxymetazoline nasal sprays, such as Afrin, can cause problems with the lining of your nasal passages. However, there are some times when Afrin or similar sprays are helpful. I have recommended it for people with colds or sinus infections before going on a plane, for example, since it is very effective in short-term use (no more than three days).

Read more here:
Is there any help for chemotherapy-induced neuropathy? - STLtoday.com

Read More...

Increased Chemotherapy Leads to Lower Quality of Life in Newly Diagnosed Ovarian Cancer – Curetoday.com

Sunday, August 16th, 2020

Patients with newly diagnosed ovarian cancer who received weekly chemotherapy reported a lower mean quality of life (QOL) compared to patients who received the standard treatment every three weeks, according to results of a recent study published in The Lancet Oncology.

The primary endpoint of the iCON8 study also found that patients who received weekly chemotherapy saw no increase in progression-free survival (PFS) compared to patients who received the standard treatment, making it a poor choice for the management of newly diagnosed ovarian cancer.

Prior to this study, the phase 3 JGOG-3016 trial in Japan found that weekly paclitaxel combined with three-weekly carboplatin improved PFS and overall survival (OS) when compared to standard treatment in Japanese patients with advanced disease. But given the increasing evidence of the difference in response to treatment between Asian and white populations, the creators of the ICON8 trial set out to build on these results and determine if the same survival advantage could be found in a mostly European population.

While PFS was the primary endpoint of the ICON8 trial, the secondary endpoints examining QOL in these patients are what the Lancet analysis focused on.

The open-label, randomized, controlled phase 3 study included patients from 117 hospital sites in the UK, Australia, New Zealand, Mexico, South Korea and the Republic of Ireland, between June 6, 2011 and November 28, 2014. All patients were then randomly assigned to one of three groups:

All patients had either epithelial ovarian, primary peritoneal or fallopian tube carcinoma (collectively termed ovarian cancer in the study) and had not received previous systemic therapy for their ovarian cancer.

Out of the 1,566 patients in the study, 1,540 completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-OV28 questionnaires. The QLQ-C30 includes questions that measure a global health status score, function scales to determine physical, role, emotional, cognitive, and social QOL, and symptom scales to measure fatigue, nausea or vomiting, pain, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. The QLQ-OV28 measures experiences more specific to ovarian cancer, including abdominal or gastrointestinal symptoms, peripheral neuropathy, chemotherapy side effects, hormonal or menopausal symptoms, and other factors.

These questionnaires were completed by patients during outpatient attendances at day one of each chemotherapy cycle, and during follow-up visits every six weeks until nine months from randomization, then every three months for the next 2 years, and finally, every six months for up to five years from randomization. Researchers also had patients complete these surveys at six-month intervals after disease progression.

Baseline questionnaires were completed by 1,438 (92%) of patients, and of the 1,280 patients available for 9-month follow-up questionnaires 882 patients (69%) contributed data to that set. When accounting for patients who dropped out of the study due to disease progression, withdrawal or death, a total of 828 patients contributed QOL data both at 9 months and baseline.

Upon examination, the researchers found no significant difference in the global health score at 9 months between the study groups, but upon a longitudinal analysis, found lower global health scores for those receiving weekly paclitaxel compared to patients who received the standard chemotherapy every three weeks.

We found no evidence of a difference in global quality of life between treatment groups at 9 months; however, patients receiving weekly treatment reported lower mean quality of life across the 9-month period after randomization, the authors concluded.

Taken together with the lack of progression-free survival benefit, these findings do not support routine use of weekly paclitaxel-containing regimens in the management of newly diagnosed ovarian cancer.

Excerpt from:
Increased Chemotherapy Leads to Lower Quality of Life in Newly Diagnosed Ovarian Cancer - Curetoday.com

Read More...

Helping Hands Free Medical Clinic continues to make impact in Marion County more than 20 years later – SCNow

Sunday, August 16th, 2020

I find the level of attention to individual patient's needs excellent, including diligent work to remove many roadblocks to primary and advanced care, he said. This is one of the most important functions of a free clinic, requiring coordination with pharmacies, state benefit programs, hospital systems, transportation, and family caregivers. It's a blessing to be associated with them.

The Mullins clinic is open on Monday and Wednesday while the Marion clinic is open Tuesdays and Thursdays. Hours of operation are from 8 a.m. to 5 p.m.

To qualify, visitors must be a Marion County resident, 18 years of age or older, not receiving any health insurance and income 200 percent below federal poverty guidelines.

For more information call 843-464-8750 or 843-423-5212.

Helping Hands Free Medical Clinic Services:

Health Education, TB Skin Tests, Labs, EKG and Radiology, Urinalysis, A1Cs, Medications, Flu & HEP A Vaccines, STD Screenings, PAP Smear Exams & Mammograms, Family Planning, a Diabetes & Hypertension Program, Cancer Screenings, Retinopathy & Neuropathy Exams, Screenings for Hearing, Dental Service Assistance, Wound Care Clinic, Cardiology Clinic, COVID-19 tests and referrals.

Here is the original post:
Helping Hands Free Medical Clinic continues to make impact in Marion County more than 20 years later - SCNow

Read More...

Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update – Yahoo Finance

Sunday, August 16th, 2020

Company successfully completes warrant repricing and exchange, with gross proceeds to total $10.5 million

Company Enters Negotiation for Potential Licensing of Neuropathies Asset

PRINCETON, NJ / ACCESSWIRE / August 14, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th, 2020 and provided a business update.

Pankaj Mohan, Ph.D., Founder and CEO commented, "During the quarter, we made exceptional progress advancing our pipeline of oncology candidates, as well as announced an exciting new program to explore opportunities in the antiviral arena. These accomplishments were complemented by our strategic licensing activities, that included a potential partnership for the development of our low-dose IL-6 asset (SON-081) in diabetic peripheral neuropathy, an indication with significant commercial potential."

First Quarter and Recent Corporate Updates

Sonnet is pleased to provide the following updates on its pipeline assets:

Initial preclinical proof-of-concept work has been completed with both GMcSF and IL-18 and with GMcSF and IL-12 in a xenograft mouse model of melanoma. This study was designed to evaluate preclinical activity of the concomitantly administered cytokines as FHAB-derived molecules, using Sonnet's Fully Human Albumin Binding (FHAB) technology, in several groups of tumor-bearing mice. Sonnet's FHAB-derived drug candidates all showed significant reduction in tumor growth compared to placebo and when compared to cytokines not derived from the Company's platform.

Additionally during the quarter, the Company executed a letter of intent to negotiate an agreement to license its SON-081 and SON-080 assets, both low-dose formulations of Interleukin 6 (IL-6), for diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) to New Life Therapeutics Pte. Ltd. of Singapore. The licensed territory would include the ASEAN countries of Singapore, Malaysia, Indonesia, Thailand, The Philippines, Cambodia, Brunei, Vietnam, Myanmar and Lao PDR. The transaction is subject to execution of a definitive agreement to be negotiated between Sonnet and New Life. Sonnet is scheduled to receive $500,000 upon final execution of the letter of intent from New Life and could receive an additional $3.5 million in license fees upon execution of the definitive agreement. The letter of intent also stipulates up to $36 million in milestone payments and a royalty of 30% on commercial sales, payable to Sonnet.

As previously announced, COVID-19 has impacted the speed at which the Company is completing some trials, but the Company remains on track to submit an IND for SON-080 in the first half of 2021 and SON-1010 in the second half of 2021. The Company also expects to accrue additional pre-clinical data for its various pipeline products over the coming months, some of which may be appropriate for presentation at upcoming medical conferences.

Fiscal 2020 Third Quarter Ended June 30, 2020 Financial Results

As previously reported, on April 1, 2020, the Company completed its merger transaction with Sonnet Sub, whereby Sonnet Sub became a wholly owned subsidiary of the Company, and the business of Sonnet Sub became that of the Company. On April 2, 2020, the Company's common stock began trading on The Nasdaq Capital Market under the symbol "SONN."

Jay Cross, CFO, elaborated on the Company's capital structure, saying, "With the warrant exchange transaction completed, we have good visibility into our pro forma fully diluted share count. At approximately 29.3 million shares, assuming the exercise of the remaining Series A warrants, the share count is significantly below the potential 39.7 million shares that could have existed under the original terms of the $19.0 million private placement transaction. Importantly, this new pro forma number includes 11.3 million Series C warrants that, if exercised, would bring in gross proceeds to the Company of $36.1 million."

About Sonnet BioTherapeutics Holdings, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Story continues

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet Biotherapeutics Investor Contact

Alan LadaSolebury Trout617-221-8006alada@soleburytrout.com

Sonnet BioTherapeutics Holdings, Inc.Balance Sheets(unaudited)

Assets

Current assets:

Cash

Prepaid expenses other current assets

Total current assets

Property and equipment

Operating lease right-of-use asset

Other assets

Total assets

Liabilities and stockholders' equity (deficit)

Current liabilities:

Related-party notes

Accounts payable

Accrued expenses

Operating lease liability

Total current liabilities

Note payable

Operating lease liability

Total liabilities

Commitments and contingencies (note 8)

Stockholders' equity (deficit):

Preferred stock; $0.0001 par value: 5,000,000 shares authorized. No shares issued or outstanding

Common stock; $0.0001 par value: 125,000,000 shares authorized; 9,200,176 and 5,547,643 issued and outstanding at June 30, 2020 and September 30, 2019, respectively

Additional paid-in capital

Accumulated deficit

Total stockholders' equity (deficit)

Total liabilities and stockholders' equity (deficit)

Sonnet BioTherapeutics Holdings, Inc.Statements of Operations(unaudited)

Operating expenses:

Research and development

Acquired in-process in-process research and development

General and administrative

Loss from operations

Interest income (expense)

Foreign exchange loss

Net loss

Per share information:

Net loss per share of common stock, basic and diluted

Weighted average shares outstanding, basic and diluted

SOURCE: Sonnet BioTherapeutics Holdings, Inc.

View source version on accesswire.com: https://www.accesswire.com/601648/Sonnet-BioTherapeutics-Provides-Fiscal-Year-Third-Quarter-Business-and-Earnings-Update

Link:
Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update - Yahoo Finance

Read More...

Page 3«..2345..10..»


2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick